Comprehensive clinical assessment: what factors are taken into account before making a therapeutic adjustment
Start with a clinical reassessment comprehensive: diagnostic confirmation, characterisation of the severity and temporal course of symptoms, baseline functional status and previous response to treatment. The following are defined realistic treatment goals and measurable, integrating objective and subjective measures (vital signs, validated scales, quality-of-life questionnaires), as well as relevant additional tests and biomarkers where indicated (e.g. renal and hepatic function, plasma levels of drugs requiring monitoring).
- Comorbidities and functional status: heart disease, COPD/asthma, kidney or liver disease, psychiatric disorders, chronic pain, frailty and risk of falls.
- Special conditions: pregnancy, breastfeeding, childhood/adolescence and old age.
- Physiological parameters: glomerular filtration rate, liver function tests, weight/BMI, nutritional status and haemodynamic variability.
- Safety record: allergies, previous adverse reactions, risk of bleeding, history of QT prolongation or serotonin syndrome.
- Interactions and contraindications: review of drug–drug and drug–food interactions (e.g. CYP and P-gp pathways), therapeutic duplications and product-specific warnings.
- Therapeutic index and monitoring: the need for close clinical or laboratory monitoring when using drugs with a narrow therapeutic index (e.g. anticonvulsants, lithium, anticoagulants, digoxin).
- Dose adjustments: dose adjustment according to renal/hepatic function, formulation, route of administration and dosing schedule; consider gradual titration and criteria for pausing or discontinuing treatment in the event of adverse events.
- Feasibility and adherence: understanding of the programme, prior adherence, accessibility and cost, social support and ability to attend follow-up appointments; assess, where appropriate, strategies for deprescribing whilst monitoring for any possible withdrawal or rebound symptoms.
- Evidence and clinical guidelines: alignment with current recommendations and an individual risk–benefit assessment, documenting uncertainties and a plan for reassessment.
Laboratory tests, imaging and vital signs that typically guide dose adjustment or intervention
Laboratory tests
A combined interpretation of test results and clinical context often supports prudent dose adjustments or specific interventions.
- Kidney function: creatinine and eGFR; renal impairment may require adjustments to drugs excreted by the kidneys to prevent accumulation.
- Liver function: ALT/AST, bilirubin, albumin, PT/INR; dysfunction may alter metabolism and protein binding, thereby increasing toxicity.
- Plasma drug concentrations: for example, digoxin, lithium, anti-epileptic drugs, aminoglycosides or vancomycin; values outside the therapeutic range should prompt gradual dose adjustments.
- Electrolytes and acid–base balance: K+, Na+, Mg2+, bicarbonate; abnormalities may affect the safety of diuretics, antiarrhythmics or ACE inhibitors/ARB-II.
- Complete blood count: Neutropenia or thrombocytopenia associated with cytotoxic agents, heparins or other medicines may necessitate a pause, a reduction in dosage or a change to the treatment regimen.
- Blood glucose and HbA1c: Persistent poor control may indicate a need to adjust the dosage of antidiabetic medication or to review drug interactions and adherence.
Diagnostic imaging
Imaging findings, when assessed alongside clinical findings and the risk-benefit balance, often lead to changes in treatment or supportive care.
- Cranial CT scan: Evidence of bleeding in patients on anticoagulants usually leads to consideration of discontinuation, reversal or a review of future doses.
- Chest X-ray or pulmonary ultrasound: signs of congestion in heart failure guide the adjustment of diuretics and fluid management.
- Doppler ultrasound Venous: confirmation of DVT to guide the initiation or adjustment of anticoagulation according to individual bleeding risk.
- Echocardiogram: Changes in ejection fraction or valve pressures may necessitate careful adjustment of beta-blockers, ACE inhibitors/ARB or diuretics.
- Ultrasound/abdominal CT scan: Evidence of advanced cirrhosis or cholestasis suggests that the doses of drugs metabolised by the liver should be reviewed.
Vital signs and monitoring
Sustained changes in vital signs generally support gradual, supervised adjustments, with safety as the priority.
- Blood pressure: Persistent hypotension or hypertension warrants a review of antihypertensive drugs, vasodilators, diuretics or sedation.
- Heart rate and heart rate (ECG): bradycardia, tachycardia or prolonged QT interval suggest that the dosage of drugs with chronotropic or proarrhythmic effects should be reassessed.
- Temperature: Persistent fever may warrant a reassessment of antimicrobial treatment and the source of the infection.
- Respiratory rate and SpO2: Tachypnoea or hypoxaemia warrant an increase in oxygen therapy and adjustment of fluid and diuretic therapy according to tolerance.
- Urine output and weight: Oliguria or rapid weight gain suggest fluid retention and may require an adjustment to diuretic therapy or fluid balance.
Risks, benefits and conservative alternatives to be considered before changing a course of treatment
Potential risks associated with changing a course of treatment
Changing a medicine, the dose or the treatment regimen may lead to new or worsening adverse events, interactions, withdrawal or rebound syndrome y clinical decompensation chronic diseases. There is also a risk of medication errors during the transition, under-dosing or over-dosing, and variations in response due to alterations in kidney or liver function, pregnancy, advanced age or fragility. Before any changes are made, the monitoring capability and the stability of the clinical picture.
Clinical benefits sought
The aim is to achieve a better risk–benefit balance, reduce the burden of adverse effects, simplify regulations to promote the adhesion and tailor the plan to the patient’s comorbidity profile and preferences. In some contexts, adjusting treatment may help to prevent complications or improve clinically relevant outcomes, always with realistic expectations; the extent of the benefit varies and must be defined by measurable objectives and review deadlines.
Conservative alternatives prior to the change
- Optimising adherence and the method of administration (e.g. inhalers or injections) and to check that the patient understands the treatment plan.
- Review interactions, duplications and polypharmacy; adjust the dose to kidney/liver function and age.
- Gradual adjustments dosage or intervals with monitoring safety and efficacy before replacing the medicine.
- Non-pharmacological strategies clinically supported (adapted physical activity, nutrition, sleep hygiene, physiotherapy, psychological therapy, health education).
- Change the formulation, route or timetable to improve tolerability without introducing new active ingredients.
- Diagnostic re-evaluation and, where appropriate, further tests where there is uncertainty about the cause of the symptoms.
- Multidisciplinary consultation and documented shared decisions where the risk is high or the case is complex.
Interactions, comorbidities and contraindications to be taken into account when considering a safe adjustment
Drug and food interactions
The pre-adjustment assessment must identify combinations that alter exposure or exacerbate adverse effects.
- Enzyme inhibitors/inducers (e.g. CYP/UGT pathways): inhibitors increase plasma levels and inducers reduce them; the grapefruit juice and herbal products such as the St John’s Wort can affect the metabolism.
- QT prolongation: Concomitant use with antiarrhythmics, certain antimicrobials or antipsychotics increases the risk of torsades; consider an ECG and avoid overlapping risks.
- Serotonin syndrome: the combination of serotonergic drugs (SSRIs/SNRIs, MAOIs, triptans, linezolid) may lead to toxicity; observe washout periods where appropriate.
- CNS and respiratory depression: opioids, benzodiazepines, alcohol and sedating antihistamines have additive effects.
- Haemorrhage: NSAIDs, anticoagulants and antiplatelet agents increase the risk of bleeding when taken together; monitor clinical signs and coagulation parameters where indicated.
- Electrolyte imbalances: risk of hyperkalaemia with IECA/ARA II, potassium-sparing diuretics and potassium supplements.
- Modified absorption: Antacids, iron or calcium can chelate drugs; elevated gastric pH caused by PPIs/H₂ blockers reduces the bioavailability of certain compounds.
Comorbidities that influence risk
Certain conditions require conservative management, longer titration intervals and specific monitoring.
- Kidney failure: accumulation of drugs or metabolites; assess estimated glomerular filtration rate and avoid nephrotoxic drugs where possible.
- Liver failure: reduced metabolism and increased hepatotoxicity; exercise caution with drugs with a high first-pass effect.
- Heart disease: history of arrhythmia, Prolonged QTc or heart failure call for caution with sympathomimetics, fluid and salt retention, and QT-prolonging agents.
- Seizure disorders: avoid medicines that lower the seizure threshold, or adjust the dosage gradually.
- COPD/sleep apnoea: increased sensitivity to CNS depressants and opioids.
- Diabetes and thyroid disorders: some treatments affect blood glucose levels or thyroid function; adjust targets and monitoring accordingly.
- Advanced age: polypharmacy, anticholinergic burden, orthostatic hypotension and the risk of falls mean that lower initial doses are recommended.
- Pregnancy and breastfeeding: to assess teratogenicity, transfer into breast milk and alternatives with a better safety profile.
Major contraindications and precautions
Before adjusting doses or changing treatments, check for any conditions that would make use of the treatment inadvisable.
- Hypersensitivity to the active ingredient or to the excipients.
- Severe target organ disease: advanced renal or hepatic impairment where the drug relies on clearance via those organs.
- Arrhythmic risk: Pre-existing QTc prolongation, a history of torsades or electrolyte imbalances in relation to QT-prolonging agents.
- Prohibited interactions: concomitant use with IMAO or other medicines with a formal contraindication; observe washout periods.
- Specific conditions: angle-closure glaucoma for potent anticholinergics; active bleeding for anticoagulants; uncontrolled hypertension for sympathomimetics.
- The need for baseline monitoring: ECG, liver and kidney function tests, complete blood count or plasma levels “where appropriate” before and after the adjustment.
Patient preferences, adherence and health goals in the decision to undergo an adjustment
The decision to make an adjustment should be based on a shared decision-making process that incorporates the patient preferences, its context and the health objectives agreed. It is useful to clarify which outcomes are relevant to the individual (symptom management, function, specific clinical events) and what level of uncertainty they are willing to accept. The objectives must be realistic and measurable within a defined timeframe, and must be weighed against the risk–benefit the expected clinical outcome and the burden associated with the change.
Before interpreting a sub-optimal response as an indication of adjustment, it is essential to systematically assess the adhesion. It is important to distinguish between intentional non-adherence (e.g. due to perceived adverse effects or personal beliefs) and unintentional non-adherence (forgetfulness, barriers to access, complexity of the treatment regimen). A review of the use of devices or of the management technique, therapeutic reconciliation and open-ended questions help to identify barriers such as adverse effects, polypharmacy, cognitive difficulties or cost, which can be addressed through simplified treatment regimens, reminders, educational support and structured follow-up.
Practical criteria for deciding on an adjustment
- Guidance and targets: to confirm that the prioritised objectives are not being met despite adequate adherence and technique.
- Safety and tolerability: consider comorbidities, drug interactions, renal/hepatic function, pregnancy and the adverse effect profile.
- Feasibility: assess the therapeutic burden (frequency, routes of administration), the need for monitoring and accessibility.
- Explicit preferences: agree on the approach, intensity and pace of change, prioritising the minimum effective and reversible adjustment wherever possible.
- Follow-up plan: define evaluation metrics, a timeframe for reviewing the impact, and criteria for maintaining, intensifying or reversing the adjustment.
